Patents by Inventor Shigekazu Nagata
Shigekazu Nagata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11692999Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.Type: GrantFiled: June 17, 2021Date of Patent: July 4, 2023Assignee: KYOTO UNIVERSITYInventors: Shigekazu Nagata, Katsumori Segawa
-
Publication number: 20220233571Abstract: An object is to provide a P2X7 receptor expression modulator. The object is achieved by a P2X7 receptor expression modulator comprising at least one member selected from the group consisting of an Eros (essential for reactive oxygen species) expression modulator and a functional modulator of Eros.Type: ApplicationFiled: May 22, 2020Publication date: July 28, 2022Applicant: OSAKA UNIVERSITYInventors: Shigekazu NAGATA, Yuta RYODEN, Katsumori SEGAWA
-
Publication number: 20210311019Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.Type: ApplicationFiled: June 17, 2021Publication date: October 7, 2021Applicant: KYOTO UNIVERSITYInventors: Shigekazu NAGATA, Katsumori SEGAWA
-
Patent number: 11073510Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.Type: GrantFiled: March 26, 2019Date of Patent: July 27, 2021Assignee: KYOTO UNIVERSITYInventors: Shigekazu Nagata, Katsumori Segawa
-
Publication number: 20190242873Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.Type: ApplicationFiled: March 26, 2019Publication date: August 8, 2019Applicant: KYOTO UNIVERSITYInventors: Shigekazu NAGATA, Katsumori SEGAWA
-
Patent number: 10295528Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.Type: GrantFiled: April 7, 2015Date of Patent: May 21, 2019Assignee: KYOTO UNIVERSITYInventors: Shigekazu Nagata, Katsumori Segawa
-
Patent number: 9857357Abstract: The disclosure relates to a method of screening a modulator of Xkr8, comprising the steps of: (1) contacting Xkr8-expressing cells with a candidate of the modulator, and (2) selecting the candidate when the candidate alters distribution of a phospholipid in plasma membrane of the cells.Type: GrantFiled: November 13, 2013Date of Patent: January 2, 2018Assignee: KYOTO UNIVERSITYInventors: Shigekazu Nagata, Jun Suzuki
-
Publication number: 20170023548Abstract: The present invention relates to a method for screening an inhibitor of ATP11C or CDC50A, comprising determining (a) exposure of phosphatidylserine on cell surface, (b) engulfment of cells by macrophages, or (c) cleavage of ATP11C by caspase. The present invention also relates to a method for inducing engulfment of cells by macrophages, comprising inhibiting ATP11C or CDC50A.Type: ApplicationFiled: April 7, 2015Publication date: January 26, 2017Applicant: KYOTO UNIVERSITYInventors: Shigekazu NAGATA, Katsumori SEGAWA
-
Patent number: 9453835Abstract: The present invention relates to a method for screening a modulator of a TMEM16 family member, which comprises the following steps: (1) treating cells expressing the TMEM16 family member with a candidate of the modulator, and (2) determining whether the candidate alters distribution of a lipid selected from phosphatidylserine, phosphatidylcholine, and galactosylceramide in plasma membrane of the cells, wherein a candidate which increases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as a modulator enhancing a function of the TMEM16 family member, and a candidate which decreases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as a modulator suppressing a function of the TMEM16 family member, and a candidate which increases distribution of phosphatidylcholine or galactosylceramide in the inner leaflet of plasma membrane compared to control is selected as a modulator enhancing a function ofType: GrantFiled: April 16, 2013Date of Patent: September 27, 2016Assignee: KYOTO UNIVERSITYInventors: Shigekazu Nagata, Jun Suzuki, Toshihiro Fujii
-
Publication number: 20150301024Abstract: The disclosure relates to a method of screening a modulator of Xkr8, comprising the steps of: (1) contacting Xkr8-expressing cells with a candidate of the modulator, and (2) selecting the candidate when the candidate alters distribution of a phospholipid in plasma membrane of the cells.Type: ApplicationFiled: November 13, 2013Publication date: October 22, 2015Inventors: Shigekazu NAGATA, Jun SUZUKI
-
Publication number: 20150079599Abstract: The present invention relates to a method for screening a modulator of a TMEM16 family member, which comprises the following steps: (1) treating cells expressing the TMEM16 family member with a candidate of the modulator, and (2) determining whether the candidate alters distribution of a lipid selected from phosphatidylserine, phosphatidylcholine, and galactosylceramide in plasma membrane of the cells, wherein a candidate which increases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as a modulator enhancing a function of the TMEM16 family member, and a candidate which decreases distribution of phosphatidylserine in the outer leaflet of plasma membrane compared to control is selected as a modulator suppressing a function of the TMEM16 family member, and a candidate which increases distribution of phosphatidylcholine or galactosylceramide in the inner leaflet of plasma membrane compared to control is selected as a modulator enhancing a function ofType: ApplicationFiled: April 16, 2013Publication date: March 19, 2015Inventors: Shigekazu Nagata, Jun Suzuki, Toshihiro Fujii
-
Patent number: 8603455Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: GrantFiled: June 10, 2009Date of Patent: December 10, 2013Assignee: Japan Science and Technology AgencyInventor: Shigekazu Nagata
-
Patent number: 8398984Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: GrantFiled: September 30, 2009Date of Patent: March 19, 2013Assignee: Japan Science and Technology AgencyInventor: Shigekazu Nagata
-
Publication number: 20100196378Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: ApplicationFiled: September 30, 2009Publication date: August 5, 2010Inventor: Shigekazu Nagata
-
Publication number: 20100136100Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: ApplicationFiled: June 10, 2009Publication date: June 3, 2010Inventor: Shigekazu Nagata
-
Patent number: 7622554Abstract: This invention provides a polypeptide useful in the field of medicines, a DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the DNA, a transformant transformed with the DNA or the recombinant DNA molecule, a process for the purification of the polypeptide, a process for the production of the polypeptide, an antibody which recognizes the polypeptide, an oligonucleotide complementary to the DNA and a screening method. Particularly this invention provides a polypeptide, which is Fas ligand or a fragment thereof. This polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This polypeptide is obtained by identifying a DNA fragment, which encodes the polypeptide, transforming a desired host with a recombinant DNA molecule, which contains the DNA fragment, and purifying the polypeptide produced by the resulting transformant.Type: GrantFiled: June 7, 2004Date of Patent: November 24, 2009Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takashi Suda, Tomohiro Takahashi, Norio Nakamura
-
Publication number: 20080226556Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: ApplicationFiled: November 13, 2007Publication date: September 18, 2008Inventor: Shigekazu Nagata
-
Patent number: 7128905Abstract: The present invention is drawn to methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.Type: GrantFiled: February 28, 2002Date of Patent: October 31, 2006Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takehiro Yatomi, Takashi Suda
-
Publication number: 20060233806Abstract: The present invention is to provide a removal promoter for apoptotic cells which is capable of immediately removing apoptotic cells in vivo by macrophages, or a removal inhibitor which inhibits the removal of apoptotic cells in vivo by macrophages. A removal promoter for apoptotic cells in vivo containing the milk fat globule-EGF factor 8-L (MFG-E8-L), MFG-E8-L mutant having removal promotion action for apoptotic cells in vivo by macrophages, or preferably a recombinant human or mouse MFG-E8-L, or a recombinant human or mouse MFG-E8-L mutant as an active ingredient is prepared. Such removal promoters specifically bind to apoptotic cells and promote the phagocytosis of apoptotic cells by macrophages by recognizing aminophospholipids such as phosphatidylserine exposed on apoptotic cell surface. On the other hand, a point mutation (D89E) MFG-E8-L mutant is used as a removal inhibitor.Type: ApplicationFiled: November 19, 2002Publication date: October 19, 2006Inventor: Shigekazu Nagata
-
Publication number: 20060089491Abstract: Abstract of the Disclosure This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognize the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body.Type: ApplicationFiled: June 7, 2004Publication date: April 27, 2006Applicants: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu NAGATA, Takashi SUDA, Tomohiro TAKAHASHI, Norio NAKAMURA